Latest France News

Apollo Minerals scored a legal win as the Administrative Court of Toulouse dismissed an NGO-led challenge that briefly stalled its Couflens tungsten project in France. The ruling removes an immediate obstacle, but an appeal window remains open.

Medical Developments International (ASX:MVP) reported a 9% revenue increase to $42.6 million and a 566% jump in net profit to $0.6 million for FY26, driven by robust growth in its Pain Management segment and expanded paediatric approvals in Europe.

WAM Global's FY2026 investment portfolio fell 4.2%, dragging the company to a $35.2 million net loss despite a 6.6 cent fully franked final dividend.

Scalare Partners offers 87 bonus options per 100 shares to eligible shareholders alongside piggyback options, aiming to mitigate dilution from upcoming convertible note conversions. Directors plan to exercise their options, with potential capital raised earmarked for working capital.

Orora’s FY26 results reveal a $616.6 million statutory loss driven by a $742.8 million Glass impairment, offset by robust growth in its Cans business and disciplined capital management.

Anteris Technologies posted a $51.7 million loss in H1 2026 amid ramped-up R&D and clinical trial activity, supported by a $320 million capital raise and Medicare reimbursement for its DurAVR heart valve trial.

Black Horse Mining Limited completed an $8 million IPO and acquired an 80% stake in the Mt Egerton Gold Project holder. The company reported a $5.87 million loss for FY26, driven by exploration costs and significant share-based payments.

Gentrack Group is set to refresh its board with three new independent directors, while two long-serving members prepare to retire by year-end, marking a strategic governance renewal.

Viridis Mining's Demonstration Plant for Mixed Rare Earth Carbonate production has outperformed Pre-Feasibility Study assumptions, achieving average magnetic rare earth oxide recoveries near 79% during steady operation in July 2026.

Mayfield Childcare has launched a $3 million entitlement offer, fully covered by major shareholder pre-commitments and partial underwriting, to bolster working capital and support its operational turnaround amid ongoing sector challenges.

Eden Innovations reported strong EdenCrete® trial results in India and North America, strategic hires for EdenShield® in defence markets, and completed a $4.05 million placement, ending the quarter debt-free with $5.2 million cash.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.